These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 1164849)

  • 1. The plasma concentration of a synthetic progestin, R 2323, released from polysilastic vaginal rings.
    Viinikka L; Victor A; Jänne O; Raynaud JP
    Contraception; 1975 Sep; 12(3):309-16. PubMed ID: 1164849
    [No Abstract]   [Full Text] [Related]  

  • 2. Intravaginal contraception with the synthetic progestin, R2010.
    Toivonen J
    Contraception; 1979 Nov; 20(5):511-8. PubMed ID: 527342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of progestin R 2323 released from vaginal rings on ovarian function.
    Johansson ED; Luukkainen T; Vartiainen E; Victor A
    Contraception; 1975 Sep; 12(3):299-307. PubMed ID: 1164848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contraceptive steroid administration by subdermal implants: serum concentrations of R-2323, estrogen and progesterone in rhesus monkeys.
    Bahgat MR; Atkinson LE
    Contraception; 1977 Mar; 15(3):335-45. PubMed ID: 880812
    [No Abstract]   [Full Text] [Related]  

  • 5. Release of contraceptive steroids from sustained release dosage forms and resulting plasma levels.
    Nash HA; Robertson DN; Jackanicz TM
    Contraception; 1978 Oct; 18(4):395-409. PubMed ID: 720073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of postpartum rhesus monkeys with progestogen: appearance in milk and effects on lactation.
    Bahgat MR; Atkinson LE; Brinson AO; Segal SJ
    Contraception; 1975 Dec; 12(6):665-78. PubMed ID: 812634
    [No Abstract]   [Full Text] [Related]  

  • 7. Contraceptive efficacy of once-weekly oral administration of 2.5 mg R 2323.
    Sakiz E; Azadian-Boulanger G; Ojasoo T; Laraque F
    Contraception; 1976 Sep; 14(3):275-84. PubMed ID: 975818
    [No Abstract]   [Full Text] [Related]  

  • 8. Contraceptive effectiveness of Silastic implants containing the progestin R-2323.
    Coutinho EM; Da Silva AR; Carreira CM; Chaves MC; Adeodato Filho J
    Contraception; 1975 Jun; 11(6):625-35. PubMed ID: 1137935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravaginal contraception with the synthetic progestin, R2323.
    Akinla O; Lähteenmäki P; Jackanicz TM
    Contraception; 1976 Dec; 14(6):671-8. PubMed ID: 1017201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Action of midcycle contraceptive (R 2323) on the human endometrium.
    Azadian-Boulanger G; Secchi J; Laraque F; Raynaud JP; Sakiz E
    Am J Obstet Gynecol; 1976 Aug; 125(8):1049-56. PubMed ID: 782250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of four different contraceptive vaginal rings: steroid serum levels, luteal activity, bleeding control and lipid profiles.
    Alvarez-Sanchez F; Brache V; Jackanicz T; Faundes A
    Contraception; 1992 Oct; 46(4):387-98. PubMed ID: 1486777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of weekly administration of an oral progestogen -R 2323- on the ovarian function.
    Victor A; Johansson ED
    Contraception; 1975 Jul; 12(1):89-94. PubMed ID: 1139951
    [No Abstract]   [Full Text] [Related]  

  • 13. Lack of clinical contraceptive efficacy of large doses of r 2323 given before implantation or after a missed period.
    Mora G; Faúndes A; Johansson ED
    Contraception; 1975 Aug; 12(2):211-20. PubMed ID: 1139957
    [No Abstract]   [Full Text] [Related]  

  • 14. Male contraception and the "unisex pill".
    Coutinho EM
    IPPF Med Bull; 1974 Jun; 8(3):3-4. PubMed ID: 4448269
    [No Abstract]   [Full Text] [Related]  

  • 15. Initial clinical studies of intravaginal rings containing norethindrone and norgestrel.
    Mishell DR; lumkin M; Jackanicz T
    Contraception; 1975 Sep; 12(3):253-60. PubMed ID: 1164845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ovarian activity and bleeding patterns during extended continuous use of a combined contraceptive vaginal ring.
    Davies GC; Feng LX; Newton JR; Dieben TO; Coelingh-Bennink HJ
    Contraception; 1992 Sep; 46(3):269-78. PubMed ID: 1451522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peripheral plasma levels of d-norgestrel in women after oral administration of d-norgestrel and when using intravaginal rings impregnated with dl-norgestrel.
    Victor A; Edqvist LE; Lindberg P; Elamsson K; Johansson ED
    Contraception; 1975 Sep; 12(3):261-78. PubMed ID: 1164846
    [No Abstract]   [Full Text] [Related]  

  • 18. The effect of oral contraceptives on hormonal cytology.
    Kauraniemi TV; Hirvonen E
    Ann Chir Gynaecol Fenn; 1974; 63(6):465-9. PubMed ID: 4441026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of a synthetic progestogen, ethylnorgestrienone, on hypothalamic-pituitary-ovarian function, cervical mucus, vaginal cytology, and endometrial morphology.
    Niaraki MA; Moghissi KS; Borin K
    Fertil Steril; 1981 Mar; 35(3):284-8. PubMed ID: 6781938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The interaction between sex hormone binding globulin and levonorgestrel released from vaginal rings in women.
    Cekan SZ; Jia M; Landgren BM; Diczfalusy E
    Contraception; 1985 Apr; 31(4):431-9. PubMed ID: 3924477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.